Live Analyst Rating Changes 1603 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Edward Nash
CG
Edward Nash
Canaccord Genuity
Wall Street Analyst
★★☆☆☆
#2290
on 13Foresight · ranked by our own returns
37%
Success Rate
-1.2%
Average Return
13 of 35 calls profitable · -9.2% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 37% of Edward Nash's ratings turned a profit when each position was held for 1 year — averaging -1.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

114 Buy 6 Hold 0 Sell
Edward's Stock Coverage 41 ratings · 2026-06-22
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
CNTB
Connect Biopharma Holdings
 Jun 17, 2026 BUY Strong Buy
+226.3% avg upside
11 analysts
$6.00
200.07% Upside
 ·
TVTX
Travere Therapeutics
 Jun 02, 2026 BUY Strong Buy
-16.0% avg upside
22 analysts
$56.00
1.57% Upside
 +21.1%
KYMR
Kymera Therapeutics
 Jun 01, 2026 BUY Strong Buy
+8.9% avg upside
36 analysts
$106.00
17.30% Upside
 +14.6%
APGE
Apogee Therapeutics
 May 28, 2026 BUY Strong Buy
+28.5% avg upside
19 analysts
$130.00
43.92% Upside
 +16.1%
CORT
Corcept Therapeutics
 May 28, 2026 BUY Buy
-45.5% avg upside
15 analysts
$135.00
68.93% Upside
 +19.6%
RANI
Rani Therapeutics Holdings
 May 20, 2026 BUY Strong Buy
+1114.2% avg upside
10 analysts
$5.00
538.99% Upside
 ·
TSE:CRDL
Cardiol Therapeutics
 May 19, 2026 BUY Strong Buy
+637.0% avg upside
6 analysts
$11.32
652.31% Upside
 ·
VERU
Veru
 May 14, 2026 BUY Strong Buy
+568.6% avg upside
10 analysts
$25.00
747.39% Upside
 +13.4%
SGMT
Sagimet Biosciences, Inc. Class A
 May 12, 2026 BUY Strong Buy
+317.1% avg upside
15 analysts
$49.00
633.54% Upside
 -9.8%
PLRX
Pliant Therapeutics
 May 12, 2026 HOLD Buy
+1821.1% avg upside
21 analysts
$3.00
158.56% Upside
 +4.2%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 May 08, 2026 BUY Strong Buy
+132.5% avg upside
17 analysts
$101.00
126.91% Upside
 -6.5%
CLDX
Celldex
 May 08, 2026 BUY Strong Buy
+20.6% avg upside
28 analysts
$62.00
91.20% Upside
 -4.5%
MDGL
Madrigal Pharmaceuticals
 May 07, 2026 BUY Strong Buy
-5.8% avg upside
31 analysts
$578.00
14.30% Upside
 -5.4%
VKTX
Viking Therapeutics
 May 04, 2026 BUY Strong Buy
+141.1% avg upside
30 analysts
$107.00
252.16% Upside
 -6.6%
KNSA
Kiniksa Pharmaceuticals
 Apr 29, 2026 BUY Strong Buy
-0.2% avg upside
11 analysts
$64.00
16.09% Upside
 -1.2%
IVA
Inventiva
 Apr 02, 2026 BUY Strong Buy
+350.1% avg upside
16 analysts
$20.00
460.23% Upside
 -33.8%
RZLT
Rezolute
 Oct 02, 2024 BUY Strong Buy
+122.8% avg upside
13 analysts
$9.00
79.26% Upside
 +95.1%
ORMP
Oramed Pharm
 May 17, 2023 HOLD Strong Buy
+394.9% avg upside
7 analysts
$2.00
48.38% Downside
 -36.6%
GLMD
Galmed Pharmaceuticals
 Aug 08, 2022 HOLD Buy
+4113.4% avg upside
13 analysts
$15.00
2486.22% Upside
 -86.5%
OBSEF
ObsEva
 Jul 29, 2022 HOLD Buy
+10799900.0% avg upside
8 analysts
$1.00
999900.07% Upside
 ·
XGN
Exagen
 May 18, 2021 BUY Strong Buy
+159.4% avg upside
10 analysts
$25.00
450.59% Upside
 -68.0%
CPRX
Catalyst Pharma
 Aug 09, 2019 BUY Strong Buy
-17.0% avg upside
15 analysts
$11.00
64.92% Downside
 -19.5%
IFRX
InflaRx
 Jun 05, 2019 HOLD Buy
+390.4% avg upside
11 analysts
$5.00
176.31% Upside
 +144.8%
WVE
Wave Life Sciences
 May 20, 2019 BUY Strong Buy
+260.5% avg upside
28 analysts
$39.00
533.20% Upside
 -55.2%
SRPT
Sarepta Therapeutics
 Feb 27, 2019 BUY Buy
+244.5% avg upside
49 analysts
$176.00
904.02% Upside
 -29.0%
QURE
uniQure
 Feb 26, 2019 BUY Strong Buy
+20.8% avg upside
29 analysts
$64.00
38.30% Upside
 +0.0%
BMRN
BioMarin Pharmaceutical
 Feb 25, 2019 BUY Strong Buy
+72.8% avg upside
52 analysts
$117.00
113.98% Upside
 -0.4%
RARE
Ultragenyx Pharmaceutical
 Jan 23, 2019 BUY Strong Buy
+142.1% avg upside
36 analysts
$71.00
158.67% Upside
 +16.2%
ANAB
AnaptysBio
 Sep 24, 2018 BUY Strong Buy
+26.1% avg upside
26 analysts
$156.00
171.16% Upside
 -62.3%
ARGX
Argenx Se
 Sep 17, 2018 BUY Strong Buy
-15.8% avg upside
46 analysts
$132.00
84.94% Downside
 +37.5%
SMMT
Summit Therapeutics
 Jun 27, 2018 HOLD Strong Buy
+112.6% avg upside
27 analysts
$4.00
70.96% Downside
 -48.6%
ELOX
Eloxx Pharmaceuticals
 Jun 25, 2018 BUY Strong Buy
+154.0% avg upside
8 analysts
$26.00
86.05% Upside
 -49.2%
ABEO
Abeona Therapeutics
 May 16, 2018 BUY Strong Buy
+195.8% avg upside
17 analysts
$23.00
298.53% Upside
 -64.5%
NBRVF
Nabriva Therapeutics
 Sep 18, 2017 BUY Buy
+13374900.0% avg upside
9 analysts
$24.00
23999899.95% Upside
 ·
ANTH
Anthera Pharmaceuticals
 May 16, 2017 HOLD Buy
+472857042.9% avg upside
9 analysts
$2.00
199999899.99% Upside
 ·
LRMR
Larimar Therapeutics
 May 05, 2017 HOLD Strong Buy
+406.3% avg upside
21 analysts
$6.00
64.85% Upside
 +43.6%
IMUX
Immunic
 Mar 07, 2017 HOLD Strong Buy
+166.0% avg upside
21 analysts
$9.00
36.68% Downside
 +26.4%
IRWD
Ironwood Pharma
 Sep 04, 2014 HOLD Buy
+235.6% avg upside
23 analysts
$10.50
196.56% Upside
 -10.8%
SGMO
Sangamo Therapeutics
 Jun 17, 2013 BUY Buy
+5844.3% avg upside
16 analysts
 — +109.4%
DCTH
Delcath Systems
 May 03, 2013 SELL Strong Buy
+82.8% avg upside
11 analysts
 — ·
ACAD
ACADIA Pharmaceuticals
 Jan 28, 2013 BUY Strong Buy
+65.9% avg upside
42 analysts
 — ·
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Edward Nash — Frequently Asked Questions
How accurate are Edward Nash's stock ratings?
Based on the calls 13Foresight could measure, about 37% of Edward's ratings were profitable over a one-year hold, with an average return of -1.2% per rating, or -9.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Edward ranked on 13Foresight?
Edward Nash is currently ranked #2290 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Edward cover?
Edward most recently has ratings on CNTB, TVTX, KYMR, APGE, CORT, RANI, TSE:CRDL, VERU, SGMT, PLRX, GPCR, CLDX and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.